Bill

Bill > HB4721


WV HB4721

WV HB4721
Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration


summary

Introduced
01/22/2026
In Committee
01/22/2026
Crossed Over
Passed
Dead

Introduced Session

2026 Regular Session

Bill Summary

The purpose of this bill is to add a provision in Schedule I drugs relating to the scheduling of crystalline polymorph psilocybin, if approved by the Food and Drug Administration and the Drug Enforcement Administration, and declare that will be lawful to prescribe, distribute and market this drug.

AI Summary

This bill proposes to amend West Virginia's controlled substances act by adding a new provision to Schedule I, which lists drugs with a high potential for abuse and no currently accepted medical use. Specifically, it states that if a crystalline polymorph psilocybin substance, such as COMP360, is approved by the U.S. Food and Drug Administration (FDA) and scheduled by the Drug Enforcement Administration (DEA), it will be lawful to prescribe, distribute, and market this drug. This change would allow for the legal use of this specific form of psilocybin for medical purposes, provided it meets the rigorous approval processes of federal agencies.

Committee Categories

Health and Social Services

Sponsors (2)

Last Action

To House Health and Human Resources (on 01/22/2026)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...